TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29142011

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate (MED/LC) diet + 28 g walnuts/day
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA+)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA+) with MED/LC diet
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate (MED/LC) diet
Number of subjects: 278

Group type: COMPARATOR
Intervention: Weight loss
Number of subjects: 278
Study: 28447545

Group type: EXPERIMENTAL
Intervention: Family-based self-management support intervention (education, social support, home visits, and telephone calls)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 157
Study: 26228998

Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 4% albumin
Number of subjects: 6

Group type: COMPARATOR
Intervention: 5% glucose
Number of subjects: 6
Study: 23910712

Group type: EXPERIMENTAL
Intervention: rhDNase
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 20613654

Group type: EXPERIMENTAL
Intervention: Female Training (FT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Male Training (MT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Female Training (FT) and Male Training (MT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both FT and MT groups
Number of subjects: 60
Study: 18369067

Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 15
Study: 16516077

Group type: EXPERIMENTAL
Intervention: Stenting with abciximab
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty with abciximab
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: Stenting without abciximab
Number of subjects: 1529

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty without abciximab
Number of subjects: 1529
Study: 12668296

Group type: COMPARATOR
Intervention: Conventional tracheal airway (ETA)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Esophageal‐Tracheal Combitube (ETC)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Adrenaline (epinephrine) via ETC
Number of subjects: 172
Study: 10518167

Group type: EXPERIMENTAL
Intervention: Psychoanalytically oriented partial hospitalization
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard psychiatric care (control)
Number of subjects: 38
Study: 8594425

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (1 mg of enoxaparin per kilogram of body weight subcutaneously twice daily)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard heparin (intravenous)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 500
Study: 1748110

Group type: COMPARATOR
Intervention: Unloaded condition (5.2 kg clothing mass)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: External load of 31.5 kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: External load of 49.4 kg
Number of subjects: 15
Study: 7128192

Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin at night
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31868666

Group type: EXPERIMENTAL
Intervention: Choreographed exercise (Choreography group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Multimodal physical therapy (Physical Therapy group)
Number of subjects: 36
Study: 31587438

Group type: EXPERIMENTAL
Intervention: SystemCHANGETM intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control group (education on healthy living after transplant)
Number of subjects: 0
Study: 27055824

Group type: EXPERIMENTAL
Intervention: Ashwagandha (300 mg) twice daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 25266601

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 43

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 43
Study: 24298762

Group type: EXPERIMENTAL
Intervention: Shao's five needling therapy combined with oxygen uptake, aerosol inhalation, and oral administration of prednisone
Number of subjects: 210

Group type: COMPARATOR
Intervention: Theophylline sustained release tablet combined with oxygen uptake, aerosol inhalation, and oral administration of prednisone
Number of subjects: 210
Study: 21904230

Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nail (n = 56)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Large fragment medial plate (n = 48)
Number of subjects: 104
Study: 19657820

Group type: EXPERIMENTAL
Intervention: Tailored decision support intervention
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard menopausal information
Number of subjects: 176
Study: 16690347

Group type: EXPERIMENTAL
Intervention: AquaRelease (nelfilcon A with additional PVA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: ocufilcon B
Number of subjects: 39
Study: 15271690

Group type: EXPERIMENTAL
Intervention: Testosterone injections (100 mg of testosterone enanthate injected weekly)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Resistance training (45 minutes three times weekly)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Testosterone injections + Resistance training
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo injections + Resistance training
Number of subjects: 47

Group type: COMPARATOR
Intervention: Testosterone injections + No training
Number of subjects: 47
Study: 11966550

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine (2 mg.ml(‐1))
Number of subjects: 115

Group type: COMPARATOR
Intervention: Ropivacaine (2 mg.ml(‐1)) with sufentanil (1 microg.ml(‐1))
Number of subjects: 115
Study: 9617977

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study: 7613799

Group type: EXPERIMENTAL
Intervention: Catheter traction for 30 min
Number of subjects: 115

Group type: COMPARATOR
Intervention: No catheter traction
Number of subjects: 115
Study: 2092965

Group type: EXPERIMENTAL
Intervention: Urapidil (30mg, 60mg, or 90mg twice daily)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5 mg/day or 12.5 or 25mg twice daily)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 165

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Urapidil and Hydrochlorothiazide
Number of subjects: 165
Study: 366257

Group type: EXPERIMENTAL
Intervention: Pilocarpine 1% with phenylephrine 0.25%
Number of subjects: 2

Group type: COMPARATOR
Intervention: Pilocarpine 1%
Number of subjects: 2
Study: 6800537

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Surgical operation
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Less conventional operations
Number of subjects: 908

Group type: COMPARATOR
Intervention: Reduction in operation rates
Number of subjects: 908
Study: 30239610

Group type: COMPARATOR
Intervention: Baseline plasma 25(OH)D >33.6 ng/mL
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Baseline plasma 25(OH)D <20 ng/mL
Number of subjects: 711
Study: 29214305

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 15760
Study: 27339840

Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stents (EES)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Drug-Eluting Balloons (DEB)
Number of subjects: 189
Study: 23800753

Group type: EXPERIMENTAL
Intervention: Regional block with sedation
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 50
Study: 22479550

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 679

Group type: COMPARATOR
Intervention: Formula/cows' milk feeding
Number of subjects: 679
Study: 20173086

Group type: EXPERIMENTAL
Intervention: Trazodone Contramid OAD (TzCOAD) 75-375 mg
Number of subjects: 0
Study: 17638640

Group type: EXPERIMENTAL
Intervention: Multimodality monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single modality monitoring (intracranial pressure monitoring)
Number of subjects: 0
Study: 16127194

Group type: EXPERIMENTAL
Intervention: heparin + exercise (walking for 60 min after heparin injection [3,000 units/day IV for 14 days], n = 6)
Number of subjects: 19

Group type: COMPARATOR
Intervention: heparin administration only (n = 6)
Number of subjects: 19

Group type: COMPARATOR
Intervention: exercise only (n = 7)
Number of subjects: 19
Study: 11832980

Group type: EXPERIMENTAL
Intervention: Preemptive epidural analgesia with 8 mL of 0.25% bupivacaine and 2 mL of fentanyl (50 microg/mL) prior to skin incision, followed by an infusion of bupivacaine 0.1% and fentanyl 10 microg/mL at 6 mL/hr.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received saline in the epidural.
Number of subjects: 0
Study: 10420027

Group type: EXPERIMENTAL
Intervention: KTP/Nd:YAG laser treatment
Number of subjects: 204

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 204
Study: 7500327

Group type: EXPERIMENTAL
Intervention: Exercise self-efficacy
Number of subjects: 1944

Group type: EXPERIMENTAL
Intervention: Previous exercise experience, satisfaction with amount of walking, depression, and outcome expectations
Number of subjects: 1944

Group type: EXPERIMENTAL
Intervention: Exercise outcome expectations
Number of subjects: 1944
Study: 2261179

Group type: EXPERIMENTAL
Intervention: Eccentric photoscreener
Number of subjects: 231

Group type: COMPARATOR
Intervention: Conventional testing
Number of subjects: 231
Study: 6106095

Group type: EXPERIMENTAL
Intervention: Intrathecal human tetanus immunoglobulin (TIG) 250 IU
Number of subjects: 97

Group type: COMPARATOR
Intervention: Intramuscular human tetanus immunoglobulin (TIG) 1000 IU
Number of subjects: 97
Study: 31590698

Group type: EXPERIMENTAL
Intervention: C-section
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Physician practices
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Health system characteristics
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Recommendations for improvement
Number of subjects: 205
Study: 31345359

Group type: EXPERIMENTAL
Intervention: 30 mg/d zinc (as zinc gluconate) for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study: 27770338

Group type: EXPERIMENTAL
Intervention: Antibiotic-loaded bone cement (ALBC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Bone cement (BC)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both ALBC and BC
Number of subjects: 39
Study: 26441467

Group type: EXPERIMENTAL
Intervention: Health coaching with mobile phone monitoring
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Health coaching without mobile phone monitoring
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (no health coaching)
Number of subjects: 131
Study: 23381840

Group type: EXPERIMENTAL
Intervention: 10 mg rivaroxaban
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 24843514

Group type: EXPERIMENTAL
Intervention: Risk factors for diabetes evaluated as odds ratios adjusted for potential confounding factors by logistic regression
Number of subjects: 9223

Group type: EXPERIMENTAL
Intervention: Age, smoking (both past and current), family history of diabetes in men
Number of subjects: 9223

Group type: EXPERIMENTAL
Intervention: Body mass index, family history of diabetes, hypertension in women
Number of subjects: 9223

Group type: EXPERIMENTAL
Intervention: Baseline HbA1c value
Number of subjects: 9223
Study: 19739499

Group type: EXPERIMENTAL
Intervention: Biobloc appliance treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 41
Study: 17966440

Group type: EXPERIMENTAL
Intervention: ACEI plus antiarrhythmic (Propafenona, 450 mg daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Antiarrhythmic (Propafenona, 450 mg daily)
Number of subjects: 36
Study: 15073669

Group type: EXPERIMENTAL
Intervention: 125 mg famciclovir 3 times daily
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 250 mg famciclovir 3 times daily
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Famciclovir (both dosages)
Number of subjects: 177
Study: 12049083

Group type: EXPERIMENTAL
Intervention: Bulk filling technique
Number of subjects: 27

Group type: COMPARATOR
Intervention: Three horizontal increments technique
Number of subjects: 27

Group type: COMPARATOR
Intervention: Pre‐polymerized composite inserts technique
Number of subjects: 27
Study: 9380326

Group type: EXPERIMENTAL
Intervention: Oral beta carotene for at least 6 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo for at least 6 months
Number of subjects: 39
Study: 8217750

Group type: EXPERIMENTAL
Intervention: Topical all‐trans‐retinoic acid (0.1% and 0.025% cream formulations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical all‐trans‐retinoic acid (0.001 to 0.025% concentrations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium lauryl sulphate
Number of subjects: 0
Study: 3302542

Group type: EXPERIMENTAL
Intervention: Cefuroxime administered intraincisionally before surgery and immediately after surgery (total 5,250 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cefuroxime administered only postoperatively (total 5,250 mg)
Number of subjects: 52
Study: 31414192

Group type: EXPERIMENTAL
Intervention: Epilepsy Self-Management Scale (ESMS) lifestyle management
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Epilepsy Self-Management Scale (ESMS) safety management
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 100
Study: 29262978

Group type: EXPERIMENTAL
Intervention: Varenicline alone
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Varenicline combined with nicotine replacement therapy (NRT)
Number of subjects: 435
Study: 26056164

Group type: EXPERIMENTAL
Intervention: Prenatal training
Number of subjects: 518

Group type: COMPARATOR
Intervention: Control group (no prenatal training)
Number of subjects: 518
Study: 22716279

Group type: EXPERIMENTAL
Intervention: Orthodontic elastic separators placed between the second premolar and first molar (compression site)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control site (contralateral quadrant)
Number of subjects: 10
Study: 22272505

Group type: EXPERIMENTAL
Intervention: Sequential presentation mode condition (visual working memory)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential delay condition (visual working memory)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulation condition (both visual and spatial working memory)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simultaneous baseline condition (visual working memory)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simultaneous delay condition (visual working memory)
Number of subjects: 0
Study: 19811624

Group type: EXPERIMENTAL
Intervention: Interdisciplinary diabetes care teams (IDCT)
Number of subjects: 2495

Group type: EXPERIMENTAL
Intervention: IDCT in Advanced Quality Improvement Program (AQIP)
Number of subjects: 2495

Group type: COMPARATOR
Intervention: Usual Quality Improvement Program (UQIP)
Number of subjects: 2495
Study: 17027560

Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Left ventricular angiography
Number of subjects: 302
Study: 12631048

Group type: EXPERIMENTAL
Intervention: Clonidine 150 microg premedication
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (oral antacid - algel hydroxide 300 mg)
Number of subjects: 32
Study: 10694308

Group type: EXPERIMENTAL
Intervention: Terbinafine 1% emulsion-gel
Number of subjects: 65

Group type: COMPARATOR
Intervention: Ketoconazole 2% cream
Number of subjects: 65
Study: 8884758

Group type: EXPERIMENTAL
Intervention: Alprazolam (APZ) 1 mg/day orally for 3 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1393414

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Oral cholecystography (OCG)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Combination of US and OCG
Number of subjects: 169
Study: 6321588

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d. for 6 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 73
Study: 31549872

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30419927

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MeD)
Number of subjects: 188

Group type: COMPARATOR
Intervention: FTO gene influence
Number of subjects: 188
Study: 25720069

Group type: EXPERIMENTAL
Intervention: Variant II Turbo system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capillarys 2 Flex Piercing system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultra2 system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HA-8160 system
Number of subjects: 0
Study: 24118853

Group type: EXPERIMENTAL
Intervention: 33°C temperature control for 24 hours after cardiac arrest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 36°C temperature control for 24 hours after cardiac arrest
Number of subjects: 0

Group type: COMPARATOR
Intervention: Myocardial infarction controls
Number of subjects: 0
Study: 21383275

Group type: EXPERIMENTAL
Intervention: School-based care group (preventive medications administered by school nurses)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: School-based care group
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: School-based care group (for children with smoke exposure)
Number of subjects: 530
Study: 19698035

Group type: EXPERIMENTAL
Intervention: Spinal-epidural anesthesia plus intravenous patient-controlled anesthesia with tramadol
Number of subjects: 180

Group type: COMPARATOR
Intervention: General anesthesia (propofol induction, maintenance with sevoflurane) plus intravenous patient-controlled anesthesia with tramadol
Number of subjects: 180
Study: 17904943

Group type: EXPERIMENTAL
Intervention: Soy milk (720 mL daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Skim milk (720 mL daily)
Number of subjects: 14
Study: 15779842

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 35
Study: 11736773

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.125% (group R)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bupivacaine 0.125% (group B)
Number of subjects: 32
Study: 7948760

Group type: EXPERIMENTAL
Intervention: Direct Fluorescent Antibody (DFA) testing
Number of subjects: 384

Group type: COMPARATOR
Intervention: Methenamine Silver Staining (MSS)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Combined use of DFA and MSS
Number of subjects: 384
Study: 3252245

Group type: EXPERIMENTAL
Intervention: Tryptophan deficient amino acid mixture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutritionally balanced amino acid mixture
Number of subjects: 0
Study: 29973252

Group type: EXPERIMENTAL
Intervention: Smartphone-delivered cognitive behavioral therapy (CBT) components including self-monitoring, cognitive restructuring, behavioral activation, assertion training, and problem solving.
Number of subjects: 0
Study: 27468953

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 819

Group type: COMPARATOR
Intervention: Women
Number of subjects: 819

Group type: COMPARATOR
Intervention: Men and Women
Number of subjects: 819
Study: 26852497

Group type: EXPERIMENTAL
Intervention: System of early diagnosis and non-pharmacological primary prevention including climatotherapeutic and physiotherapeutic methods, personalized dietary therapy, hypoxic-hypercapnic factors, and educational programs.
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 310
Study: 23546935

Group type: EXPERIMENTAL
Intervention: Delamanid-containing regimens (treatment group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo-containing regimens (control group)
Number of subjects: 38
Study: 21722684

Group type: EXPERIMENTAL
Intervention: 10 μg CHO hepatitis B vaccine
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: 20 μg CHO hepatitis B vaccine
Number of subjects: 642

Group type: COMPARATOR
Intervention: Comparison of 10 μg and 20 μg groups
Number of subjects: 642
Study: 18307589

Group type: EXPERIMENTAL
Intervention: peg-IFN alpha 2b plus ribavirin
Number of subjects: 383

Group type: COMPARATOR
Intervention: IFN alpha-2b plus ribavirin
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: peg-IFN alpha-2b
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: NNRTI-containing antiretroviral regimens
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Severe weight loss
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Weight loss >5%
Number of subjects: 383
Study: 16689009

Group type: EXPERIMENTAL
Intervention: Jinghua Weikang Capsule (JWC), 160 mg 3 times per day, orally before meals for 4 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: famotidine 20 mg twice per day, orally before meals for 4 weeks
Number of subjects: 200
Study: 12673785

Group type: EXPERIMENTAL
Intervention: PPARγ2 Ala homozygotes (n = 6)
Number of subjects: 284
Study: 10946310

Group type: EXPERIMENTAL
Intervention: Recombinant human IL-10 (25 microg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9056005

Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg intravenously (i.v.) every 8 hours (q8h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg intravenously (i.v.) every 12 hours (q12h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg orally (p.o.) every 8 hours (q8h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg orally (p.o.) every 12 hours (q12h)
Number of subjects: 12
Study: 8285777

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg/day/1.73 m2 surface area)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ranitidine (20 mg/kg/day)
Number of subjects: 32
Study: 2957052

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 1 g daily
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Provera (100- and 200-mg tablets)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Farlutal (500-mg tablets)
Number of subjects: 29